ASPCF News and Press, Acerus Pharmaceuticals Corp From 05/05/20

Acerus Pharmaceuticals Corporation (TSX:ASP; OTCQB:ASPCF) will announce its first quarter 2020 financial and operating results on Tuesday May 12, 2020 before the market opens. The company will host a conference call on Tuesday, May 12, 2020 at 8:30 a.m. Eastern Time. To access the call li...

Acerus Pharmaceuticals Corporation (TSX:ASP) today announced the appointment of Dr. Geoff Cotton, MB BS, MBA to its Board of Directors. Dr. Cotton is a healthcare executive, venture capital adviser, and angel investor with 20 years experience in the pharmaceutical industry. He spent over ...

NATESTO ® Increases Serum Testosterone and Improves Hypogonadal Symptoms While Preserving Sperm Parameters Within Normal Range Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) (“Acerus” or the “Company”) today announced the acceptance of the N...

Health Canada requires additional data related to avanafil drug substance Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) (“Acerus” or the “Company”) today announced that it has received a Notice of Deficiency (“NOD”) for its av...

Acerus Pharmaceuticals ( OTCQB:ASPCF ) has issued an update on its activities in relation to worldwide COVID-19 pandemic. More news on: Acerus Pharmaceuticals Corporation, Healthcare stocks news, Read more ...

Supply Chain remains intact Progress continues with respect to build-out of Acerus’ US commercial presence Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX:ASP, OTCQB:ASPCF) today issued an update on the Company’s ac...

Acerus Pharmaceuticals Corporation (TSX:ASP; OTCQB :ASPCF) will announce financial results for the three and twelve month periods ending December 31, 2019 on Wednesday, March 4, 2020 before the market opens. About Acerus Acerus Pharmaceuticals Corporation is a Canadian-based special...

Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX:ASP, OTCQB:ASPCF) is pleased to announce today’s closing of the refinancing transactions previously announced on February 12, 2020 (the “Refinancing Transactions”). Acerus rece...

Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX:ASP, OTCQB:ASPCF) today announced that it has entered into agreements with First Generation Capital, Inc. (“First Generation”) in respect of an equity financing and debt-to-equity con...

Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX:ASP, OTCQB:ASPCF) today announced the acceptance of two NATESTO ® clinical studies for presentation at the American Urological Association’s AUA2020 Scientific Program. The AUA2020 mee...